EUVIMEDOpdag EUVIMED
MetaanalyseÜbersichtsarbeit

Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis

Carlos Taxonera iD, David Olivares iD, Olga N López-García iD, Cristina Alba

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17386 ↗

At a glance

Metaanalyse in Alimentary Pharmacology & Therapeutics, 2023. Written by Carlos Taxonera and 3 co-authors. Institution: Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Car…. Major MEDLINE topics: Colitis, Ulcerative, Biological Products. Cited 36 times so far (Crossref); 37 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Evidence on real‐world outcomes of ustekinumab for ulcerative colitis (UC) patients is needed.

Aims

To summarise evidence on the real‐world outcomes of ustekinumab for UC and conduct a meta‐analysis of effectiveness and safety data.

Methods

A systematic search was conducted through September 2022 in electronic databases for observational studies evaluating ustekinumab for UC. A random‐effects meta‐analysis model was used to calculate the pooled effect sizes (percentages or incidence rates [IRs]) of effectiveness and safety outcomes.

Results

In all, 19 studies were included with 3786 patients. More than 92% of patients were previously treated with any biologic, 61.1% with both anti‐TNF and vedolizumab and 16.4% with any biologic and tofacitinib. Clinical remission was achieved in 45.4% at week 8 (95% CI: 30.1%–60.6%), 43.8% (38.4%–49.2%) at weeks 12–16, 44.6% (35.9%–53.3%) at month 6, and 50.6% (36.3%–64.8%) at month 12. Response was achieved in 61.2%, 59.4%, 65.2% and 76.8% at weeks 8, 12–16, month 6 and 12, respectively. CS‐free remission was achieved in 18.7%, 36.8%, 34.5% and 39% at weeks 8, 12–16, month 6 and 12, respectively. Overall, 58.2% of patients had endoscopic improvement at month 12. Almost 30% of the patients needed dose escalation, which was effective in 40% of these patients. The IRs of colectomy, adverse events (AEs), serious AEs and serious infections were 4.8, 7.9, 0.8 and 0.3 per 100 patient‐years, respectively.

Conclusions

This meta‐analysis confirms the effectiveness and safety of ustekinumab in a highly treatment‐refractory population of UC patients.

Subjects

MeSH terms (MEDLINE)

Colitis, UlcerativeBiological ProductsHumansUstekinumabTumor Necrosis Factor InhibitorsColectomyTreatment OutcomeRemission Induction

Author keywords

effectivenessmeta-analysisreal worldsafetysystematic reviewulcerative colitisustekinumab

Substances

UstekinumabTumor Necrosis Factor InhibitorsBiological Products

Authors and institutions

  • Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos [IdISSC], Madrid, Spain.
  • Gastroenterology Department, Hospital Clínico San Carlos, Madrid, Spain.

ORCID profiles: Carlos Taxonera, David Olivares, Olga N López-García

Cite

APA

Taxonera, C., Olivares, D., López-García, O. N., & Alba, C. (2023). Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17386

Vancouver

Taxonera C, Olivares D, López-García ON, Alba C. Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17386

BibTeX
@article{Taxonera2023,
  author = {Taxonera, Carlos and Olivares, David and López-García, Olga N and Alba, Cristina},
  title = {Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17386}
}
Start for free →